welcome to i-tech hiv/aids clinical seminar series 3 rd june 2010 contraception in the setting of...
TRANSCRIPT
![Page 1: Welcome to I-TECH HIV/AIDS Clinical Seminar Series 3 rd June 2010 Contraception in the Setting of HIV R. Scott McClelland, MD, MPH](https://reader036.vdocuments.mx/reader036/viewer/2022062516/56649e595503460f94b52915/html5/thumbnails/1.jpg)
Welcome to I-TECH HIV/AIDS Clinical Seminar Series
3rd June 2010
Contraception in the Setting of HIV
R. Scott McClelland, MD, MPH
![Page 2: Welcome to I-TECH HIV/AIDS Clinical Seminar Series 3 rd June 2010 Contraception in the Setting of HIV R. Scott McClelland, MD, MPH](https://reader036.vdocuments.mx/reader036/viewer/2022062516/56649e595503460f94b52915/html5/thumbnails/2.jpg)
Outline
• Brief ‘world view’ of contraception and HIV
• What are the benefits of contraception?
• Contraception in the setting of HIV
• Clinical case studies in contraception– Safety– Efficacy– Side effects– Management in different clinical scenarios
![Page 3: Welcome to I-TECH HIV/AIDS Clinical Seminar Series 3 rd June 2010 Contraception in the Setting of HIV R. Scott McClelland, MD, MPH](https://reader036.vdocuments.mx/reader036/viewer/2022062516/56649e595503460f94b52915/html5/thumbnails/3.jpg)
Learning Objectives
• Be able to provide HIV-positive women with a clear explanation of the potential benefits and risks of different contraceptive choices
• Feel comfortable with basic clinical decision making for initiation and continuation of contraception in HIV-positive women
![Page 4: Welcome to I-TECH HIV/AIDS Clinical Seminar Series 3 rd June 2010 Contraception in the Setting of HIV R. Scott McClelland, MD, MPH](https://reader036.vdocuments.mx/reader036/viewer/2022062516/56649e595503460f94b52915/html5/thumbnails/4.jpg)
Global Use of Contraception
• ~800 million women use modern methods of contraception– ~150 million use hormonal
contraceptives– Others use intra-uterine
contraceptive devices, barriers, and tubal ligation
![Page 5: Welcome to I-TECH HIV/AIDS Clinical Seminar Series 3 rd June 2010 Contraception in the Setting of HIV R. Scott McClelland, MD, MPH](https://reader036.vdocuments.mx/reader036/viewer/2022062516/56649e595503460f94b52915/html5/thumbnails/5.jpg)
Unmet Contraceptive NeedRef: Network Vol 23, number 3,2004. Family Health International
![Page 6: Welcome to I-TECH HIV/AIDS Clinical Seminar Series 3 rd June 2010 Contraception in the Setting of HIV R. Scott McClelland, MD, MPH](https://reader036.vdocuments.mx/reader036/viewer/2022062516/56649e595503460f94b52915/html5/thumbnails/6.jpg)
Benefits of Contraception in the Setting of HIV
• Contraception reduces pregnancy and may provide additional health, social, and economic benefits.– Groups should discuss briefly, then rank top
three benefits of contraception. Consider both general benefits and specific advantages of contraception in the setting of HIV.
![Page 7: Welcome to I-TECH HIV/AIDS Clinical Seminar Series 3 rd June 2010 Contraception in the Setting of HIV R. Scott McClelland, MD, MPH](https://reader036.vdocuments.mx/reader036/viewer/2022062516/56649e595503460f94b52915/html5/thumbnails/7.jpg)
Benefits of Contraception
• Avoid unplanned pregnancies– Potential for obstetrical complications– Spacing pregnancies benefits the health of
women, infants, and children
• Family planning empowers women, reducing gender inequality
• HIV-positive women may wish to reduce risk of vertical transmission by preventing further pregnancies
![Page 8: Welcome to I-TECH HIV/AIDS Clinical Seminar Series 3 rd June 2010 Contraception in the Setting of HIV R. Scott McClelland, MD, MPH](https://reader036.vdocuments.mx/reader036/viewer/2022062516/56649e595503460f94b52915/html5/thumbnails/8.jpg)
Case 1
• 24 y.o. HIV+ woman presents for 6 week post-partum visit. She initiated ART during pregnancy with CD4=226. She would like to avoid another pregnancy.– Can she be offered hormonal
contraception?
![Page 9: Welcome to I-TECH HIV/AIDS Clinical Seminar Series 3 rd June 2010 Contraception in the Setting of HIV R. Scott McClelland, MD, MPH](https://reader036.vdocuments.mx/reader036/viewer/2022062516/56649e595503460f94b52915/html5/thumbnails/9.jpg)
Many Women Living with HIV Remain Sexually Active
• Abstinence eliminates sexual transmission risk, but often not possible or desired by women or partners
• Dual protection minimizes HIV/STI transmission risk and lowers risk of pregnancy
![Page 10: Welcome to I-TECH HIV/AIDS Clinical Seminar Series 3 rd June 2010 Contraception in the Setting of HIV R. Scott McClelland, MD, MPH](https://reader036.vdocuments.mx/reader036/viewer/2022062516/56649e595503460f94b52915/html5/thumbnails/10.jpg)
Case 1
• 24 y.o. HIV+ woman presents for 6 week post-partum visit. She initiated ART during pregnancy with CD4=226. She would like to avoid another pregnancy.– Will contraception influence
the risk of HIV progression?
![Page 11: Welcome to I-TECH HIV/AIDS Clinical Seminar Series 3 rd June 2010 Contraception in the Setting of HIV R. Scott McClelland, MD, MPH](https://reader036.vdocuments.mx/reader036/viewer/2022062516/56649e595503460f94b52915/html5/thumbnails/11.jpg)
Hormonal Contraception andHIV Progression
• Secondary analysis from 1 RCT suggests increased disease progression with HC compared to intrauterine device (IUD)1
• 7 prospective cohort studies suggest HC in chronic HIV doesn’t significantly change CD4, plasma viral load, or mortality2,3
1. Stringer et al. AIDS 2009; 23: 1377-822. Curtis et al. AIDS 2009; 23 Supplement 1:S55-S673. Polis et al. CROI 2010, San Francisco, Feb 2010, abstract 152
![Page 12: Welcome to I-TECH HIV/AIDS Clinical Seminar Series 3 rd June 2010 Contraception in the Setting of HIV R. Scott McClelland, MD, MPH](https://reader036.vdocuments.mx/reader036/viewer/2022062516/56649e595503460f94b52915/html5/thumbnails/12.jpg)
Hormonal Contraception vs. IUD in HIV+ Women
• 599 postpartum women in Lusaka, Zambia• RCT IUD vs. hormonal contraception• Followed for at least 2 years• Primary endpoint: Safety and efficacy of
intrauterine device vs. hormonal contraception• Secondary endpoints:
– Time to CD4<200– Time to death– Combined endpoint including either time to CD4<200 or
death
Stringer AJOG 2007:197:144.e1-144.e8
![Page 13: Welcome to I-TECH HIV/AIDS Clinical Seminar Series 3 rd June 2010 Contraception in the Setting of HIV R. Scott McClelland, MD, MPH](https://reader036.vdocuments.mx/reader036/viewer/2022062516/56649e595503460f94b52915/html5/thumbnails/13.jpg)
Hormonal Contraception vs. IUD in HIV+ Women
• Only one episode of PID in IUD arm• Higher rate of discontinuation in IUD arm• Pregnancy higher in HC vs. IUD
– HR 2.2 (95% CI 1.2-2.4)
• Mortality did not differ significantly– HR 1.4 (95% CI 0.7-3.0)
• Faster progression to CD4<200 with hormonal contraception compared to IUD– HR 1.6 (95% CI 1.04-2.03)
![Page 14: Welcome to I-TECH HIV/AIDS Clinical Seminar Series 3 rd June 2010 Contraception in the Setting of HIV R. Scott McClelland, MD, MPH](https://reader036.vdocuments.mx/reader036/viewer/2022062516/56649e595503460f94b52915/html5/thumbnails/14.jpg)
Hormonal Contraception vs. IUD in HIV+ Women
CD4 decline
Death
![Page 15: Welcome to I-TECH HIV/AIDS Clinical Seminar Series 3 rd June 2010 Contraception in the Setting of HIV R. Scott McClelland, MD, MPH](https://reader036.vdocuments.mx/reader036/viewer/2022062516/56649e595503460f94b52915/html5/thumbnails/15.jpg)
Hormonal Contraception vs. IUD in HIV+ Women
CD4 decline
Death•Time to CD4<200 or death faster in HC vs. IUD
• HR 1.6 (95% CI 1.1-2.3)
CD4 declineordeath
![Page 16: Welcome to I-TECH HIV/AIDS Clinical Seminar Series 3 rd June 2010 Contraception in the Setting of HIV R. Scott McClelland, MD, MPH](https://reader036.vdocuments.mx/reader036/viewer/2022062516/56649e595503460f94b52915/html5/thumbnails/16.jpg)
Study Summary: Hormonal Contraception vs. IUD in HIV+ Women
• IUD appeared safe and was more effective than HC at preventing pregnancy
• No difference in mortality• Time to CD4<200 longer with IUD vs. HC• Limitations
– ~30% withdrew or lost to follow-up– ~30% discontinued allocated method– Postnatal population; can we generalize to
other women?
![Page 17: Welcome to I-TECH HIV/AIDS Clinical Seminar Series 3 rd June 2010 Contraception in the Setting of HIV R. Scott McClelland, MD, MPH](https://reader036.vdocuments.mx/reader036/viewer/2022062516/56649e595503460f94b52915/html5/thumbnails/17.jpg)
Hormonal Contraception inHIV+ Women
• 319 post-partum women in Nairobi1
– No effect on CD4 or plasma VL to 24 months in Depo-Provera or OCP compared to no HC
• US Women’s Interagency HIV Study2
– Plasma VL not influenced by HC– Small increase in CD4 over long-term follow-up
• 213 women initiating HC in Mombasa3
– No increase in plasma VL over 2 months1. Richardson AIDS 2007; 21:749-532. Cejtin AIDS 2003;17:1702-43. Wang AIDS 2004;18:205-9
![Page 18: Welcome to I-TECH HIV/AIDS Clinical Seminar Series 3 rd June 2010 Contraception in the Setting of HIV R. Scott McClelland, MD, MPH](https://reader036.vdocuments.mx/reader036/viewer/2022062516/56649e595503460f94b52915/html5/thumbnails/18.jpg)
Hormonal Contraception and Time to AIDS or Death: Rakai, Uganda
• 625 women followed from HIV acquisition
• Use of HC associated with lower risk of AIDS/death aHR (0.70, 95%CI 0.50-0.97)– Effect appeared to be present only after median
time to AIDS/death (4.4 years)– Compared to women using non-hormonal
contraception, HC users had similar risk of progression
Polis et al. CROI 2010, San Francisco, Feb 2010, Abstract 152
![Page 19: Welcome to I-TECH HIV/AIDS Clinical Seminar Series 3 rd June 2010 Contraception in the Setting of HIV R. Scott McClelland, MD, MPH](https://reader036.vdocuments.mx/reader036/viewer/2022062516/56649e595503460f94b52915/html5/thumbnails/19.jpg)
Hormonal Contraception andHIV Progression
• Majority of evidence (from cohort studies) suggests that initiating HC in HIV+ women does not increase disease progression– One RCT suggested increased progression, but
with several important limitations
![Page 20: Welcome to I-TECH HIV/AIDS Clinical Seminar Series 3 rd June 2010 Contraception in the Setting of HIV R. Scott McClelland, MD, MPH](https://reader036.vdocuments.mx/reader036/viewer/2022062516/56649e595503460f94b52915/html5/thumbnails/20.jpg)
Case 2
• 27 y.o. woman reports sex work and has been screened periodically for HIV with multiple prior negative tests. Uses Depo-Provera to prevent pregnancy. She now has a positive HIV test.– Will Depo-Provera use at the
time of HIV acquisition influence the natural history of her HIV infection?
http://www.street-papers.org/eastern-asia/
![Page 21: Welcome to I-TECH HIV/AIDS Clinical Seminar Series 3 rd June 2010 Contraception in the Setting of HIV R. Scott McClelland, MD, MPH](https://reader036.vdocuments.mx/reader036/viewer/2022062516/56649e595503460f94b52915/html5/thumbnails/21.jpg)
Hormonal Contraception andHIV Progression
• Effect may differ depending on the timing of hormonal contraception in relation to HIV-1 acquisition– Hormonal contraception initiation during chronic
HIV infection (e.g. Case 1)– Hormonal contraception at the time of HIV
acquisition (e.g. Case 2)
![Page 22: Welcome to I-TECH HIV/AIDS Clinical Seminar Series 3 rd June 2010 Contraception in the Setting of HIV R. Scott McClelland, MD, MPH](https://reader036.vdocuments.mx/reader036/viewer/2022062516/56649e595503460f94b52915/html5/thumbnails/22.jpg)
Depo-Provera at Time ofHIV Acquisition
• Indirect evidence from surrogate endpoints– Women using DMPA at the time
of HIV acquisition have• Higher set-point plasma viral load• Greater viral diversity at infection• Viral diversity is associated with
more rapid CD4 decline
Sagar et al. J Virol 2003; 77:12921-12926Sagar M et al. AIDS 2004;18:615-619.
![Page 23: Welcome to I-TECH HIV/AIDS Clinical Seminar Series 3 rd June 2010 Contraception in the Setting of HIV R. Scott McClelland, MD, MPH](https://reader036.vdocuments.mx/reader036/viewer/2022062516/56649e595503460f94b52915/html5/thumbnails/23.jpg)
Hormonal Contraception andHIV Progression
• Majority of evidence (from cohort studies) suggests that initiating HC in HIV+ women does not increase disease progression– One RCT suggested increased progression, but
with several important limitations
• HC at time of infection may influence diversity of the infecting viral population, set point VL, and rate of CD4 decline– Unknown effect on morbidity and mortality
![Page 24: Welcome to I-TECH HIV/AIDS Clinical Seminar Series 3 rd June 2010 Contraception in the Setting of HIV R. Scott McClelland, MD, MPH](https://reader036.vdocuments.mx/reader036/viewer/2022062516/56649e595503460f94b52915/html5/thumbnails/24.jpg)
Case 3
• 30 y.o. HIV+ woman with CD4=440 desires oral contraceptive pills (OCPs) to prevent pregnancy. Which of the following does WHO recommend prior to initiating OCPs?– A) Medical History and blood pressure– B) Pap Smear– C) Breast examination– D) STI screening– E) All of the above
![Page 25: Welcome to I-TECH HIV/AIDS Clinical Seminar Series 3 rd June 2010 Contraception in the Setting of HIV R. Scott McClelland, MD, MPH](https://reader036.vdocuments.mx/reader036/viewer/2022062516/56649e595503460f94b52915/html5/thumbnails/25.jpg)
Case 3
• 30 y.o. HIV+ woman with CD4=440 desires oral contraceptive pills (OCPs) to prevent pregnancy. Which of the following does WHO recommend prior to initiating OCPs?– A) Medical History and blood pressure– B) Pap Smear– C) Breast examination– D) STI screening– E) All of the above
![Page 26: Welcome to I-TECH HIV/AIDS Clinical Seminar Series 3 rd June 2010 Contraception in the Setting of HIV R. Scott McClelland, MD, MPH](https://reader036.vdocuments.mx/reader036/viewer/2022062516/56649e595503460f94b52915/html5/thumbnails/26.jpg)
Screening prior to Hormonal Contraceptive Initiation
• Careful medical history and BP are recommended.– Other elements of health
screening advisable, but not required for initiation of hormonal contraception
![Page 27: Welcome to I-TECH HIV/AIDS Clinical Seminar Series 3 rd June 2010 Contraception in the Setting of HIV R. Scott McClelland, MD, MPH](https://reader036.vdocuments.mx/reader036/viewer/2022062516/56649e595503460f94b52915/html5/thumbnails/27.jpg)
Screening prior to Hormonal Contraceptive Initiation
• Which element of medical history and exam would be a contraindication to OCPs?– A) Smokes regularly, ~20 cigarettes/day– B) History of leg blood clot after long bus ride– C) Current blood pressure 138/88– D) History of hypertension during pregnancy
with normal blood pressure on present exam– E) All of the above would be contraindications to
OCPs in this patient
![Page 28: Welcome to I-TECH HIV/AIDS Clinical Seminar Series 3 rd June 2010 Contraception in the Setting of HIV R. Scott McClelland, MD, MPH](https://reader036.vdocuments.mx/reader036/viewer/2022062516/56649e595503460f94b52915/html5/thumbnails/28.jpg)
Screening prior to Hormonal Contraceptive Initiation
• Which element of medical history and exam would be a contraindication to OCPs?– A) Smokes regularly, ~20 cigarettes/day– B) History of leg blood clot after long bus ride– C) Current blood pressure 138/88– D) History of hypertension during pregnancy
with normal blood pressure on present exam– E) All of the above would be contraindications to
OCPs in this patient
![Page 29: Welcome to I-TECH HIV/AIDS Clinical Seminar Series 3 rd June 2010 Contraception in the Setting of HIV R. Scott McClelland, MD, MPH](https://reader036.vdocuments.mx/reader036/viewer/2022062516/56649e595503460f94b52915/html5/thumbnails/29.jpg)
Contraindications to OCPs
• Pregnancy• Prior thromboembolic event or stroke• History of estrogen-dependent tumor• Active liver disease• Undiagnosed abnormal uterine bleeding• Hypertriglyceridemia• Age >35 AND smoking >15 cigarettes daily• Age >35 with migraine• Migraine with aura (any age)• Poorly controlled hypertension
![Page 30: Welcome to I-TECH HIV/AIDS Clinical Seminar Series 3 rd June 2010 Contraception in the Setting of HIV R. Scott McClelland, MD, MPH](https://reader036.vdocuments.mx/reader036/viewer/2022062516/56649e595503460f94b52915/html5/thumbnails/30.jpg)
Case 3
• 30 y.o. HIV+ woman with CD4=440 starts OCPs on the first Sunday after her menses. What is the annual risk of pregnancy with typical use?– A) 0.1%– B) 1.0%– C) 4%– D) 8%– E) 12%
![Page 31: Welcome to I-TECH HIV/AIDS Clinical Seminar Series 3 rd June 2010 Contraception in the Setting of HIV R. Scott McClelland, MD, MPH](https://reader036.vdocuments.mx/reader036/viewer/2022062516/56649e595503460f94b52915/html5/thumbnails/31.jpg)
Case 3
• 30 y.o. HIV+ woman with CD4=440 starts OCPs on the first Sunday after her menses. What is the annual risk of pregnancy with typical use?– A) 0.1%– B) 1.0%– C) 4%– D) 8%– E) 12%
![Page 32: Welcome to I-TECH HIV/AIDS Clinical Seminar Series 3 rd June 2010 Contraception in the Setting of HIV R. Scott McClelland, MD, MPH](https://reader036.vdocuments.mx/reader036/viewer/2022062516/56649e595503460f94b52915/html5/thumbnails/32.jpg)
Pregnancy Rates in First Year
Typical Use Correct Use
Male Condom 15% 2%
Depo-Provera 3% <1%
IUD <1% <1%
OCP (E/P) 8% <1%
Contraceptive Technology, 19th Ed. 2007
![Page 33: Welcome to I-TECH HIV/AIDS Clinical Seminar Series 3 rd June 2010 Contraception in the Setting of HIV R. Scott McClelland, MD, MPH](https://reader036.vdocuments.mx/reader036/viewer/2022062516/56649e595503460f94b52915/html5/thumbnails/33.jpg)
Case 3
• 30 y.o. HIV+ woman with CD4=440 starting OCPs (E/P with 30 mcg ethinyl estradiol). She should be advised to use backup contraception:– A) Until next menses if she misses a single dose– B) For 7 days if she misses a single dose– C) For 1 month after missing 3 consecutive doses– D) For 7 days if she misses 3 consecutive doses– E) None of the above
![Page 34: Welcome to I-TECH HIV/AIDS Clinical Seminar Series 3 rd June 2010 Contraception in the Setting of HIV R. Scott McClelland, MD, MPH](https://reader036.vdocuments.mx/reader036/viewer/2022062516/56649e595503460f94b52915/html5/thumbnails/34.jpg)
Case 3
• 30 y.o. HIV+ woman with CD4=440 starting OCPs (E/P with 30 mcg ethinyl estradiol). She should be advised to use backup contraception:– A) Until next menses if she misses a single dose– B) For 7 days if she misses a single dose– C) For 1 month after missing 3 consecutive doses– D) For 7 days if she misses 3 consecutive doses– E) None of the above
![Page 35: Welcome to I-TECH HIV/AIDS Clinical Seminar Series 3 rd June 2010 Contraception in the Setting of HIV R. Scott McClelland, MD, MPH](https://reader036.vdocuments.mx/reader036/viewer/2022062516/56649e595503460f94b52915/html5/thumbnails/35.jpg)
Missed Doses
WHO. Family Planning Handbook
![Page 36: Welcome to I-TECH HIV/AIDS Clinical Seminar Series 3 rd June 2010 Contraception in the Setting of HIV R. Scott McClelland, MD, MPH](https://reader036.vdocuments.mx/reader036/viewer/2022062516/56649e595503460f94b52915/html5/thumbnails/36.jpg)
Case 4
• 32 y.o. HIV+ woman was diagnosed with HIV/TB co-infection and CD4=236. Now on AZT, 3TC, NVP (month 5) and in her 5th month of TB treatment (continuation phase with INH+Rifampicin). Also taking daily Septrin. She asks about family planning.
WHO. Family Planning Handbook
![Page 37: Welcome to I-TECH HIV/AIDS Clinical Seminar Series 3 rd June 2010 Contraception in the Setting of HIV R. Scott McClelland, MD, MPH](https://reader036.vdocuments.mx/reader036/viewer/2022062516/56649e595503460f94b52915/html5/thumbnails/37.jpg)
Case 4
• What medications may interact with hormonal contraceptives?– A) Rifampicin– B) Isoniazid– C) Nevirapine– D) All of the above– E) A and C
![Page 38: Welcome to I-TECH HIV/AIDS Clinical Seminar Series 3 rd June 2010 Contraception in the Setting of HIV R. Scott McClelland, MD, MPH](https://reader036.vdocuments.mx/reader036/viewer/2022062516/56649e595503460f94b52915/html5/thumbnails/38.jpg)
Case 4
• What medications may interact with hormonal contraceptives?– A) Rifampicin– B) Isoniazid– C) Nevirapine– D) All of the above– E) A and C
![Page 39: Welcome to I-TECH HIV/AIDS Clinical Seminar Series 3 rd June 2010 Contraception in the Setting of HIV R. Scott McClelland, MD, MPH](https://reader036.vdocuments.mx/reader036/viewer/2022062516/56649e595503460f94b52915/html5/thumbnails/39.jpg)
Drug Interactions
• Metabolism of steroid hormones increased– Rifampicin– NNRTIs– Some anticonvulsants
• Metabolism of steroid hormones decreased– Lopinavir boosted with ritonavir (Kaletra/Aluvia)
![Page 40: Welcome to I-TECH HIV/AIDS Clinical Seminar Series 3 rd June 2010 Contraception in the Setting of HIV R. Scott McClelland, MD, MPH](https://reader036.vdocuments.mx/reader036/viewer/2022062516/56649e595503460f94b52915/html5/thumbnails/40.jpg)
Case 4
• Based on potential drug interactions in this patient taking AZT, 3TC, NVP, INH, Rif, and Septrin, which contraceptive regimen may be expected to have benefits generally outweighing risks:– A) Progesterone-only pills– B) Combined oral contraceptive pills– C) Depot Medroxyprogesterone acetate (Depo-Provera)– D) None of the above, she should use a non-hormonal
method for contraception
![Page 41: Welcome to I-TECH HIV/AIDS Clinical Seminar Series 3 rd June 2010 Contraception in the Setting of HIV R. Scott McClelland, MD, MPH](https://reader036.vdocuments.mx/reader036/viewer/2022062516/56649e595503460f94b52915/html5/thumbnails/41.jpg)
Case 4
• Based on potential drug interactions in this patient taking AZT, 3TC, NVP, INH, Rif, and Septrin, which contraceptive regimen may be expected to have benefits generally outweighing risks:– A) Progesterone-only pills– B) Combined oral contraceptive pills– C) Depot Medroxyprogesterone acetate (Depo-Provera)– D) None of the above, she should use a non-hormonal
method for contraception
![Page 42: Welcome to I-TECH HIV/AIDS Clinical Seminar Series 3 rd June 2010 Contraception in the Setting of HIV R. Scott McClelland, MD, MPH](https://reader036.vdocuments.mx/reader036/viewer/2022062516/56649e595503460f94b52915/html5/thumbnails/42.jpg)
Drug Interactions
• There are generally fewer clinically significant interactions with Depo Provera
• Contraceptive efficacy remains high despite theoretical interactions
WHO. Family Planning Handbook
![Page 43: Welcome to I-TECH HIV/AIDS Clinical Seminar Series 3 rd June 2010 Contraception in the Setting of HIV R. Scott McClelland, MD, MPH](https://reader036.vdocuments.mx/reader036/viewer/2022062516/56649e595503460f94b52915/html5/thumbnails/43.jpg)
Case 4
• 32 y.o. HIV+ woman was with HIV/TB co-infection and CD4=236. On AZT, 3TC, NVP, INH, Rif, and Septrin. Initiated Depo-Provera within 5 days of menses. She was given a follow-up visit for 12 weeks later, but arrived 10 days late for the scheduled visit. The WHO recommends:– A) Give her next injection now without pregnancy test– B) Pregnancy test now; if negative give next injection– C) Use condoms until next menses, then re-initiate
hormonal contraception
![Page 44: Welcome to I-TECH HIV/AIDS Clinical Seminar Series 3 rd June 2010 Contraception in the Setting of HIV R. Scott McClelland, MD, MPH](https://reader036.vdocuments.mx/reader036/viewer/2022062516/56649e595503460f94b52915/html5/thumbnails/44.jpg)
Case 4
• 32 y.o. HIV+ woman was with HIV/TB co-infection and CD4=236. On AZT, 3TC, NVP, INH, Rif, and Septrin. Initiated Depo-Provera within 5 days of menses. She was given a follow-up visit for 12 weeks later, but arrived 10 days late for the scheduled visit. The WHO recommends:– A) Give her next injection now without pregnancy test– B) Pregnancy test now; if negative give next injection– C) Use condoms until next menses, then re-initiate
hormonal contraception
![Page 45: Welcome to I-TECH HIV/AIDS Clinical Seminar Series 3 rd June 2010 Contraception in the Setting of HIV R. Scott McClelland, MD, MPH](https://reader036.vdocuments.mx/reader036/viewer/2022062516/56649e595503460f94b52915/html5/thumbnails/45.jpg)
Late for Depo-Provera?
• WHO 2008 update allows a grace period of up to 4 weeks without need for pregnancy testing
• Based on Steiner et. al. Contraception 2008– On time 0.6 (95%CI 0.33-0.92)
pregnancy/100 p-y– 2 weeks 0.0 (95%CI 0.00-1.88)
pregnancy/100 p-y– 4 weeks 0.4 (95%CI 0.01-2.29)
pregnancy/100 p-y
![Page 46: Welcome to I-TECH HIV/AIDS Clinical Seminar Series 3 rd June 2010 Contraception in the Setting of HIV R. Scott McClelland, MD, MPH](https://reader036.vdocuments.mx/reader036/viewer/2022062516/56649e595503460f94b52915/html5/thumbnails/46.jpg)
Case 4
• 32 y.o. HIV+ woman on ART, TB treatment, and Depo-Provera. Side effects of DMPA include:– A) Increased risk of endometrial cancer– B) Reduced bone mineral density– C) Increased risk of deep venous thrombosis– D) A and C– E) All of the above
![Page 47: Welcome to I-TECH HIV/AIDS Clinical Seminar Series 3 rd June 2010 Contraception in the Setting of HIV R. Scott McClelland, MD, MPH](https://reader036.vdocuments.mx/reader036/viewer/2022062516/56649e595503460f94b52915/html5/thumbnails/47.jpg)
Case 4
• 32 y.o. HIV+ woman on ART, TB treatment, and Depo-Provera. Side effects of DMPA include:– A) Increased risk of endometrial cancer– B) Reduced bone mineral density– C) Increased risk of deep venous thrombosis– D) A and C– E) All of the above
![Page 48: Welcome to I-TECH HIV/AIDS Clinical Seminar Series 3 rd June 2010 Contraception in the Setting of HIV R. Scott McClelland, MD, MPH](https://reader036.vdocuments.mx/reader036/viewer/2022062516/56649e595503460f94b52915/html5/thumbnails/48.jpg)
Depo-Provera Side Effects
• Menstrual changes
• Weight changes
• Decreased bone mineral density– BMD decreased by 0.5-3.5% after one year and
by 5.7-7.5% after two years– Most important in young women who have not
attained peak bone mass and in peri-menopausal women
ACOG Committee. Obstet Gynecol 2008; 112:727.
![Page 49: Welcome to I-TECH HIV/AIDS Clinical Seminar Series 3 rd June 2010 Contraception in the Setting of HIV R. Scott McClelland, MD, MPH](https://reader036.vdocuments.mx/reader036/viewer/2022062516/56649e595503460f94b52915/html5/thumbnails/49.jpg)
Depo-ProveraNon-Contraceptive Benefits
• Depo-Provera associated with 80% lower risk of endometrial cancer1
• No increase in risk for ovarian, cervical, hepatic malignancy
• In contrast to combined OCPs:– No increased production of coagulation factors– No increase in DVT, stroke, or MI– No adverse effects on blood pressure
![Page 50: Welcome to I-TECH HIV/AIDS Clinical Seminar Series 3 rd June 2010 Contraception in the Setting of HIV R. Scott McClelland, MD, MPH](https://reader036.vdocuments.mx/reader036/viewer/2022062516/56649e595503460f94b52915/html5/thumbnails/50.jpg)
Case 5
• 37 year old woman presents to clinic for initial evaluation for HIV. CD4=177. No history of significant illness. She had a Copper T IUD inserted 3 years ago. What is recommended for her contraception?– A) Leave the IUD in place– B) Remove IUD and recommend Depo-Provera– C) Remove IUD and recommend barrier method
until she is on ART at least 6 months
![Page 51: Welcome to I-TECH HIV/AIDS Clinical Seminar Series 3 rd June 2010 Contraception in the Setting of HIV R. Scott McClelland, MD, MPH](https://reader036.vdocuments.mx/reader036/viewer/2022062516/56649e595503460f94b52915/html5/thumbnails/51.jpg)
Case 5
• 37 year old woman presents to clinic for initial evaluation for HIV. CD4=177. No history of significant illness. She had a Copper T IUD inserted 3 years ago. What is recommended for her contraception?– A) Leave the IUD in place– B) Remove IUD and recommend Depo-Provera– C) Remove IUD and recommend barrier method
until she is on ART at least 6 months
![Page 52: Welcome to I-TECH HIV/AIDS Clinical Seminar Series 3 rd June 2010 Contraception in the Setting of HIV R. Scott McClelland, MD, MPH](https://reader036.vdocuments.mx/reader036/viewer/2022062516/56649e595503460f94b52915/html5/thumbnails/52.jpg)
IUD for Women with HIV
• Women with HIV or with AIDS but on ART and clinically well can have IUD inserted
• Women with AIDS, not on ART or not clinically well should not have IUD inserted
• If a woman develops AIDS and has IUD in place, it does not have to be removed
![Page 53: Welcome to I-TECH HIV/AIDS Clinical Seminar Series 3 rd June 2010 Contraception in the Setting of HIV R. Scott McClelland, MD, MPH](https://reader036.vdocuments.mx/reader036/viewer/2022062516/56649e595503460f94b52915/html5/thumbnails/53.jpg)
Summary
• Contraceptive services important for comprehensive HIV care
• Initiating contraception does not increase HIV progression
• Contraception similar in HIV+ and HIV- women– Encourage dual method use
including a barrier method– Consider drug interactions